The Medicines Discovery Catapult (MDC) recently hosted a series of webinars with guest speakers from its CRO partner network. The series covered all aspects of the drug discovery process, and XenoGesis, who became a MDC CRO partner in 2019, was invited to speak on two of the webinars, both of which are now available online:
Optimising the Compound
Richard Weaver, XenoGesis’ Founder and CEO, presented on ‘optimising ADME and PK properties: common mistakes and how to identify and resolve the key issues.’ Access webinar.
Understanding the PK/PD Relationship
Graham Trevitt, XenoGesis’ Chief Scientific Officer, presented on ‘principles and modelling of pharmacokinetic and pharmacodynamic relationships.’ Access webinar.
The Medicines Discovery Catapult is a national facility, based at Alderley Park in Cheshire, connecting the UK community to accelerate innovative drug discovery. Funded by Innovate UK, the MDC brings together a fragmented sector of industry, academia, charities, technologists, services, finance companies, SMEs and start-ups. Together they turn good science into new, high-value products and services that are used to improve productivity across the sector.